atezolizumab + bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin

This is a **combination therapy** of five anti-cancer agents: - **Atezolizumab** is a monoclonal antibody targeting PD-L1, acting as a checkpoint inhibitor to stimulate anti-tumor immune response. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thereby reducing tumor blood supply. - **5-Fluorouracil** is a pyrimidine analog acting as an antimetabolite, inhibiting thymidylate synthase and disrupting DNA synthesis in cancer cells. - **Leucovorin** (folinic acid) is used to enhance the efficacy of 5-fluorouracil by stabilizing its binding to thymidylate synthase. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that causes DNA cross-linking and apoptosis of malignant cells. This combination is primarily being investigated and used for **advanced or metastatic colorectal cancer** and may also be in trials or used off-label for other solid tumors. The regimen leverages immunotherapy (**atezolizumab**), anti-angiogenic therapy (**bevacizumab**), and cytotoxic chemotherapy (**5-fluorouracil, leucovorin, oxaliplatin**) to provide a multifaceted attack on cancer cell survival and proliferation[3][4].

Other names

FOLFOX + Atezolizumab + Bevacizumab